It's akin to a real-life game of "Top Trumps" or intense Poker.
Two dynamic men's healthtech brands full of testosterone, raising each other big cards in their foray into partnerships and sponsorships with elite Australian sports clubs, particularly in the NRL and the AFL.
Mosh and Pilot are known for some eye-catching, progressive adverts across multiple channels, but recently they have seen the power of reaching men through Sport.
How so?
Moshās Partnerships (so far):
Pilotās Partnerships (so far):
Why so?
A good chunk of Aussie men love footy, no matter the code. But generally speaking, NRL and AFL rule the roost.
According to Roy Morganās analysis and data, The AFLās biggest audience demographic are generally people under 35 years old, with the NRL sitting in the 50 to 64 year old group.
Although Roy Morgan stopped doing this annual survey after 2020, the results are revealing. TV viewership for the AFL sat at just over 7.5 million, with 56% of viewers male. The NRL saw over 5.7 million viewers and 61% male.
These eyeballs are intensified during the Finals Seriesā for both codes, 3.6 million tuning in to the 2021 NRL Grand Final and 3.9 million for the 2021 AFL Grand Final.
Then you consider the sizeable social media followings of the biggest NRL teams, very likely a daily destination for hardcore NRL fans, and you can see why these partnerships are a sound investment.
Melbourne Storm alone has 535,000 Facebook followers and 300,000 Instagram followers. Curiously unlike the other partnerships listed above, Moshās logo will not be on the main playersā kit but on the physios and trainerās gear (we strongly suspect the pockets couldnāt go THAT deep for full coverage on Australiaās biggest supported NRL Team).
How many more sports teams will these (and other brands) snare in 2022?
All we know is we will be watching closely to see the battle of the menās healthtech brands when St Kilda take on Richmond in the AFL on Sunday 3 April.
Go browse Pilotās website here and Moshās offering here.
Get your short, sharp shot of (mainly) australian healthtech by signing up to dose here.
Comments